Rating on Array BioPharma (NASDAQ:ARRY) is Set to Outperform. Its Reconfirms by Wells Fargo with $33 Target.

June 29, 2018 - By Clara Lewis

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo

Big Money Sentiment increased to 1.74 in 2018 Q1. It has change of 0.44, from 2017Q4’s 1.3. The ratio is positive due to Array BioPharma Inc. positioning: 16 sold and 54 reduced. 55 funds acquired stakes and 67 increased stakes. Investors holded 194.11 million in 2017Q4 but now own 189.71 million shares or 2.27% less.

Quantitative Systematic Strategies Limited Liability has 0.05% invested in Array BioPharma Inc. (NASDAQ:ARRY). 40,133 were reported by Perceptive Advsrs. Prelude Capital Mngmt Ltd Co reported 46,252 shs stake. Pinnacle Assoc Limited holds 0.83% or 2.60 million shs in its capital. Thompson Davis And Co, Virginia-based fund reported 125 shs. Moreover, Parametric Assocs Llc has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 207,628 shs. Nj State Employees Deferred Compensation Plan, a New Jersey-based fund reported 20,000 shs. Creative Planning holds 0% or 31,888 shs in its capital. D E Shaw And accumulated 14,218 shs or 0% of the stock. Columbus Circle Investors stated it has 1.13 million shs. North Star Corp reported 0.14% in Array BioPharma Inc. (NASDAQ:ARRY). Century accumulated 1.59M shs. Meeder Asset Incorporated reported 737 shs or 0% of all its holdings. Sg Americas Limited Company holds 16,065 shs. Bain Cap Pub Equity Mngmt Limited Liability invested 0.18% of its capital in Array BioPharma Inc. (NASDAQ:ARRY).

Array BioPharma Inc. had 11 selling transactions and 0 buys since January 16, 2018. This’s net activity of $6.95 million. 7,500 shs valued at $102,975 were sold by Haddock Jason on Tuesday, January 16. On Friday, March 9 Sandor Victor sold $2.76M worth of Array BioPharma Inc. (NASDAQ:ARRY).

Reiterated Array BioPharma (NASDAQ:ARRY) Rating.

Wells Fargo’s Expert analysts have $33 target price which means upside potential of 98.08 % on Array BioPharma (NASDAQ:ARRY). a research note of the firm was disclosed on Thursday, 28 June.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

A total of 7 analysts rate Array Biopharma (NASDAQ:ARRY) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:ARRY) has 13 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Thursday, June 28 Wells Fargo maintained Array BioPharma Inc. (NASDAQ:ARRY) rating. Wells Fargo has “Outperform” rating and $33 target. On Monday, June 25 the firm has “Buy” rating by Piper Jaffray given. On Tuesday, February 6 the company was maintained by Stifel Nicolaus. On Monday, June 25 Cantor Fitzgerald maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Overweight” rating. The stock rating was maintained by Cowen & Co with “Buy” on Thursday, May 10. On Tuesday, February 6 the rating was maintained by SunTrust with “Buy”. On Wednesday, February 7 Leerink Swann maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Outperform” rating. The stock rating was maintained by Cowen & Co with “Buy” on Tuesday, June 5. On Sunday, January 21 the company was maintained by Cowen & Co. On Wednesday, February 7 the rating was maintained by Cowen & Co with “Buy”.

Ticker’s shares touched $16.66 during the last trading session after 1.42% change.Currently Array BioPharma Inc. is uptrending after 92.14% change in last June 29, 2017. ARRY has also 1.40M shares volume. ARRY outperformed the S&P500 by 79.57%.

Array BioPharma Inc. (NASDAQ:ARRY)’s earnings report is expected on August, 8., as reported by RTT. Last year’s EPS was $-0.17, while now analysts expect change of 47.06 % down from current $-0.25 EPS. After $-0.11 EPS report previous quarter, Wall Street now predicts 127.27 % negative EPS growth of Array BioPharma Inc..

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The company has $3.51 billion market cap. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Last it reported negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

For more Array BioPharma Inc. (NASDAQ:ARRY) news brought out recently go to: Benzinga.com, Fool.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” brought out on June 28, 2018, “George Soros Bought This Clinical-Stage Biotech Stock. Should You?” on May 31, 2018, “Key events next week – healthcare” with a publish date: June 21, 2018, “3 Biotechs With Huge FDA Decisions in June” and the last “Jordyn Fantuzzi” with publication date: June 28, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: